Positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The study was evaluating a new checkpoint inhibitor tiragolumab and its checkpoint inhibitor atezolizumab compared to atezolizumab alone.
Tiragolumab is a novel immunotherapy that binds to TIGIT, an immune checkpoint protein found on immune cells. Atezolizumab is a PD-L1 checkpoint inhibitor. Both TIGIT and PD-L1 are involved in immune suppression. Blocking both pathways has the potential for improving anti-tumor activity.
Full data data will be presented during at an oral abstract session.
